FVH 1
Alternative Names: FVH-1; FVH1 (DNA-based influenza vaccine) - Inovio; Influenza H1N1 seasonal influenza vaccine - Inovio; INO 3605; INO 3609; SynCon® H1HA consensus DNA vaccine - Inovio; SynCon® universal H1N1 influenza vaccine - InovioLatest Information Update: 16 Jul 2016
At a glance
- Originator University of Pennsylvania
- Developer Inovio Pharmaceuticals
- Class Influenza A virus H1N1 vaccines; Influenza virus DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(In the elderly, Prevention, In volunteers) in Canada (Intradermal, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in USA (Intradermal, Injection)
- 01 Mar 2015 Inovio Pharmaceuticals and University of Manitoba complete enrolment in its Phase-I trial for Influenza-A virus H1N1 subtype (prevention in elderly volunteers) in Canada (NCT01587131)